Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 33Breast Neoplasms 25Rectal Neoplasms 23Esophageal Neoplasms 22Stomach Neoplasms 19Squamous Cell Carcinoma of Head and Neck 18Glioblastoma 16Pancreatic Neoplasms 14Lung Neoplasms 14Head and Neck Neoplasms 12Colorectal Neoplasms 11Sarcoma 10Brain Neoplasms 10Neoplasms 9Colonic Neoplasms 8Adenocarcinoma Of Esophagus 7Melanoma 6Glioma 6Esophageal Squamous Cell Carcinoma 6Ovarian Neoplasms 5Oropharyngeal Neoplasms 5Hypopharyngeal Neoplasms 5Carcinoma, Ovarian Epithelial 5Adenocarcinoma of Lung 5Prostatic Neoplasms 4Mouth Neoplasms 4Gliosarcoma 4Fallopian Tube Neoplasms 4Central Nervous System Neoplasms 4Carcinoma, Squamous Cell 4

Interventions

tocotrienol, delta 1Surgical Procedures, Operative 1Sulindac 1Immunohistochemistry 1Erlotinib Hydrochloride 1Congresses as Topic 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Pancreatic Intraductal Neoplasms × Surgical Procedures, Operative × Clear all
NCT00482625 2014-10-16

Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Terminated
6 enrolled 8 charts
Gastrointestinal

Pancreatic Intraductal Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡